“The incidence of CVC-associated venous thromboembolism (CVC-VTE) is 1.7 per 1000 catheter days. Risk factors for CVC-VTE include the patient’s underlying cancer, a history of previous thrombotic events and the location and type of CVC.” Jasti and Streiff (2014).
Reference:
Jasti, N. and Streiff, M.B. (2014) Prevention and treatment of thrombosis associated with central venous catheters in cancer patients. Expert Review of Hematology. August 31st. [epub ahead of print].
[ctt tweet=”Prevention and treatment of thrombosis associated with central venous catheters in cancer patients http://ctt.ec/f1Yl3+ @ivteam #ivteam” coverup=”f1Yl3″]
Abstract:
Central venous catheters (CVC) play an essential role in the management of cancer patients. Venous thrombosis is a common complication of CVC. The incidence of CVC-associated venous thromboembolism (CVC-VTE) is 1.7 per 1000 catheter days. Risk factors for CVC-VTE include the patient’s underlying cancer, a history of previous thrombotic events and the location and type of CVC. Anticoagulant prophylaxis is not effective for CVC-VTE. Anticoagulation alone is the preferred initial treatment for CVC-VTE. CVC removal may be considered in refractory cases or when anticoagulation is contraindicated. Thrombolytic therapy is reserved for patients with limb-threatening thrombosis or thrombosis unresponsive to conventional treatment. Anticoagulation should be continued for at least 3 months or as long as the CVC is present.
Thank you to our partners for supporting IVTEAM
[slideshow_deploy id=’23788′]
